Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - bortezomib - multiple myeloma - antineoplastic agents - bortezomib as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.bortezomib in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.bortezomib in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

idt australia ltd - thalidomide -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

idt australia ltd - thalidomide -

Νότια Αφρική - Αγγλικά - South African Health Products Regulatory Authority (SAHPRA)

key oncologics (pty) ltd - capsules - see ingredients - each capsule contains thalidomide 50,0 mg

Ιαπωνία - Αγγλικά - すりの適正使用協議会 RAD-AR Council, Japan

fujimoto pharmaceutical corporation - thalidomide - capsule with orange opaque cap imprinted with "サリドマイド" and white opaque body imprinted with "サレド100", major axis: approx. 18.0 mm, minor axis: approx. 6.3 mm

Ιαπωνία - Αγγλικά - すりの適正使用協議会 RAD-AR Council, Japan

fujimoto pharmaceutical corporation - thalidomide - capsule with orange opaque cap imprinted with "サリドマイド" and white opaque body imprinted with "サレド100", major axis: approx. 18.0 mm, minor axis: approx. 6.3 mm

Ιαπωνία - Αγγλικά - すりの適正使用協議会 RAD-AR Council, Japan

fujimoto pharmaceutical corporation - thalidomide - capsule with orange opaque cap imprinted with "サリドマイド" and white opaque body imprinted with "サレド100", major axis: approx. 18.0 mm, minor axis: approx. 6.3 mm

Ιαπωνία - Αγγλικά - すりの適正使用協議会 RAD-AR Council, Japan

fujimoto pharmaceutical corporation - thalidomide - capsule with green opaque cap imprinted with "サリドマイド" and white opaque body imprinted with "サレド25", major axis: approx. 14.3 mm, minor axis: approx. 5.3 mm

Ιαπωνία - Αγγλικά - すりの適正使用協議会 RAD-AR Council, Japan

fujimoto pharmaceutical corporation - thalidomide - capsule with green opaque cap imprinted with "サリドマイド" and white opaque body imprinted with "サレド25", major axis: approx. 14.3 mm, minor axis: approx. 5.3 mm